Epicutaneous patch testing in drug hypersensitivity syndrome (DRESS) by Santiago, F et al.
Contact Dermatitis 2010: 62: 47–53
Printed in Singapore. All rights reserved
© 2010 John Wiley & Sons A/S
CONTACT DERMATITIS
Epicutaneous patch testing in drug
hypersensitivity syndrome (DRESS)
Felicidade Santiago1, Margarida Gonc¸alo1, Ricardo Vieira1, So´nia Coelho2 and Ame´rico Figueiredo1
1Department of Dermatology, Coimbra University Hospital, Coimbra, and 2Department of Dermatology,
Hospital Infante D. Pedro, Aveiro, Portugal
Background: In some patterns of cutaneous adverse drug reactions, and depending on the culprit drug,
patch testing has been helpful in confirming its cause. Its value in Drug Rash with Eosinophilia and
Systemic Symptoms (DRESS) has not been established in a large cohort of patients.
Objective: The aim of the present study is to evaluate the safety and usefulness of patch testing in
DRESS.
Patients/Methods: Between January 1998 and December 2008, we studied 56 patients with DRESS
induced by antiepileptic agents in 33 patients (59%), allopurinol in 19 (34%) and sulfasalazine,
cotrimoxazole, tenoxicam, and amoxicillin in 1 patient each (7%).
Results: A positive patch test reaction was observed in 18 patients (32.1%), of which 17 were with
antiepileptics and 1 with tenoxicam. In the antiepileptic group, carbamazepine alone was responsible for
13 of 17 positive reactions (76.5%). Patch tests with allopurinol and its metabolite were negative in all
cases attributed to this drug.
Conclusions: In this study, patch testing was a safe and useful method in confirming the culprit drug in
DRESS induced by antiepileptic drugs, whereas it had no value in DRESS induced by allopurinol. The
pathogenesis of DRESS is not yet entirely clarified, but positive patch tests suggest a drug-dependent
delayed hypersensitivity mechanism.
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Drug hypersensitivity syndrome – also known as
‘Drug Rash with Eosinophilia and Systemic Symp-
toms’ (DRESS) – is an uncommon, idiosyncratic
adverse drug reaction with a delayed onset, a pro-
longed course, and a fatality rate of around 10–40%.
The number of causative drugs is expanding. The
most frequent are aromatic antiepileptics such as
carbamazepine, phenytoin and phenobarbital, dap-
sone, allopurinol, minocycline, and antiretroviral
drugs like nevirapine and abacavir (1–4).
The pathogenesis of DRESS is complex and not
fully understood: (i) genetic deficiency of detoxify-
ing enzymes such as epoxide hydrolase, resulting
in the accumulation of toxic drug metabolites (1);
(ii) certain HLA haplotypes predispose to DRESS,
like HLA-B*5701 for abacavir and HLA-B*5801
for allopurinol (5, 6); (iii) virus – drug interactions,
as in patients where HHV-6 reactivates during
DRESS (7); (iv) drug-induced immunosuppression
followed by an inflammatory immune recovery
syndrome is another possible explanation (8); and
(v) drug-specific T-cells have been isolated from
the blood and skin in DRESS induced by lamot-
rigine and carbamazepine, therefore suggesting a
T-cell-mediated reaction (9–11). Recently, DRESS
was classified under a delayed type IVb hypersen-
sitivity reaction, where T-helper type 2 cells play
a significant role (12–14), even though in abacavir
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hypersensitivity CD8+ T-cells seem to be preferen-
tially involved (6).
To confirm the responsible agent in DRESS,
rechallenge with the suspected drug, considered
the ‘gold standard’ in other drug eruptions, is
not advised due to the risk of a life-threatening
reaction (15). Lymphocyte transformation/activation
testing is cumbersome to perform, not standardized
for most drugs, with a low sensitivity and speci-
ficity, and, therefore, it is mainly used in research
centres (12, 16). It is also reported to be negative
during the acute phase of DRESS (17).
Patch testing, performed in the study of drug
eruptions, is not fully standardized, but it can be
helpful in confirming the imputability of a drug
in several patterns of cutaneous adverse drug reac-
tions where delayed hypersensitivity mechanisms
are involved. Positive patch tests occur more fre-
quently in maculopapular exanthemata, acute gen-
eralized exanthematous pustulosis and fixed drug
eruptions. In Stevens-Johnson syndrome and toxic
epidermal necrolysis, patch testing is seldom pos-
itive (18). There are no large studies evaluating
the utility of patch testing patients with DRESS.
There are several controlled studies, with large
numbers of patients, some with well-characterized
patterns of drug eruptions and including cases
of DRESS, but the results are usually evaluated
as a whole (15, 19). Apart from the pattern of
cutaneous adverse drug reactions, reactivity on
patch testing is highly dependent on the culprit
drug (15). Although the main drugs involved in
DRESS have also been implicated in other cuta-
neous adverse drug reactions, it is important to eval-
uate if patch test reactivity is similar in this reaction
pattern.
The aim of the present study was to evaluate the
safety and usefulness of patch testing in this severe,
potentially life-threatening adverse drug reaction,
where rechallenge is contraindicated and intrader-
mal testing is not recommended as a first line
study.
Patients and Methods
Patient selection and characterization
From January 1998 to December 2008, in the
Dermatology Department of Coimbra University
Hospital, almost exclusively in the inpatient unit,
84 patients (50 females and 34 males with a mean
age of 56.7 years) were diagnosed with DRESS. The
diagnosis was based on the presence of a minimum
of three criteria defined by Bocquet et al. (3) and on
the scoring system proposed by RegiSCAR study
group (20).
For the present study, and according to the French
Pharmacovigilance criteria proposed by Moore
et al. (21) and modified by Be´gaud et al. (22),
patients were included when one drug could be
identified with an intrinsic imputability score of 3
(likely) or 4 (very likely), or, at least, one drug had
a higher or much higher imputability score than the
other drugs taken concomitantly by the patient.
Out of the 84 patients diagnosed in the depart-
ment, only 56 patients (38 females and 18 males)
with a mean age of 52.9 ± 21.2 years (range,
12–93) were available for performing patch test-
ing. Some patients, due to their age, co-morbidities,
multiple drug regimen or persistent immunosuppres-
sion for other diseases, were not included in the
present study. According to the RegiSCAR crite-
ria, 11 patients were possible cases (3 scored 2;
8 scored 3), 30 patients were probable cases (13
scored 4; 17 scored 5) and 15 patients were def-
inite cases (8 scored 6; 4 scored 7; 3 scored 8).
As we did not perform skin biopsies or autoimmu-
nity studies in older patients, according to RegiS-
CAR criteria the DRESS scores were rather low in
some patients.
Based on the clinical data and chronology,
antiepileptic agents were the most frequently sus-
pected triggering agents in 33 patients (59%) fol-
lowed by allopurinol in 19 (34%). In three patients
(one from carbamazepine and two from allopuri-
nol) an accidental drug re-exposure with recurrence
of the skin and systemic symptoms reinforced drug
imputability. Other drugs (sulfasalazine, cotrimoxa-
zole, tenoxicam, and amoxicillin) had a high clinical
imputability score in four patients (7%).
In the 56 patients, cutaneous manifestations of
DRESS developed within 28.5 ± 9.7 days (range,
5–60) after drug administration and consisted on
a generalized maculopapular rash involving more
than 50% of the body surface in 51 patients (91%)
or erythroderma in 5 (9%), and facial oedema
in 39 (69.6%). Systemic manifestations included
pyrexia in 39 patients (69.6%), lymphadenopa-
thy in 23 (41%) and liver involvement in 47
(83.9%), 5 of whom suffered temporary, severe
liver failure. Increased serum creatinine and/or
urea nitrogen was observed in 12 patients (21.4%),
and 4 patients (7.1%) had pulmonary manifes-
tations. Atypical circulating lymphocytes were
found in 3 patients (5.3%) and eosinophilia (>800
eosinophils/μl) in 30 (53.6%), 12 of them with
more than 1500 eosinophils/μl. All patients recov-
ered with systemic steroids and early withdrawal
of the culprit drug, with a slowly progressive
resolution of skin and systemic symptoms (mean
29.4 days). Aromatic antiepileptics were replaced
by sodium valproate with a very good toler-
ance; in one case of carbamazepine-induced
DRESS, administration of phenytoin 20 days
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later induced a reactivation of the skin and liver
manifestations.
Patch testing
After informed patient consent, patch tests were
performed 6 weeks to 6 months after complete
healing of the adverse drug reaction, and at least
1 month after discontinuation of systemic corticos-
teroids, according to the proposed guidelines for
performing patch tests in cutaneous adverse drug
reactions (19).
Patch tests were applied for 2D on the upper
back, using Finn® Chambers on Scanpor tape®
(Epitest Ltd., Oy). Readings were performed at
D2 and D3 or D4 according to the International
Contact Dermatitis Research Group guidelines, with
the advice of a referral reading at D7 in case of a
late reaction. Only 1+ or more intense reactions were
considered.
All patients were patch tested with the European
baseline series of contact allergens, with the culprit
drug, with chemically or pharmacologically related
drugs [series of antiepileptics, antibiotics, or non-
steroidal anti-inflammatory drugs (NSAIDs)] and
with other drugs introduced in the previous weeks.
Patch tests were performed with the powder of
the drug supplied by the pharmaceutical industry
in a pure form (>95%) and appropriately diluted in
our laboratory or, more recently, with prepared drug
allergens obtained from Chemotechnique® Diag-
nostics, Vellinge, Sweden. As we could not obtain
the pure substance for Topamax® (Topiramate) and
Salazopirine® (Sulfasalazine), we used the powder
of the commercial drug for patch testing.
When antiepileptics were suspected, the 33
patients were tested with carbamazepine diluted
in petrolatum (pet.) in several concentrations (1%,
5%, 10% pet. in all and 20% pet. additionally in
20 patients), lamotrigine (1%, 10% pet.), phenytoin
(5%, 10% pet.), phenobarbital (5%, 10% pet.),
diazepam (1%, 10% pet.), and, in 3 patients, also
with Topamax® powder at 30% in water and
pet.
In the 19 cases where allopurinol was suspected,
apart from allopurinol tested at 1–10–20% pet. in
all patients, in 9 patients patch tests were performed
also with 8-oxypurinol (5–10% pet.), and in 3
patients with allopurinol and oxypurinol at 10% in
ethanol and water. In three patients, both allopurinol
and oxypurinol in the highest concentrations in pet.
were applied after tape stripping (23).
As control subjects for allopurinol and antiepilep-
tics we have patch tested more than 50 patients with
adverse drug reaction to other drugs and patients
previously exposed to the drugs but with no reac-
tion. In the case of Topamax®, 17 controls with an
Fig. 1. Positive patch tests with carbamazepine at D2.
Fig. 2. Positive patch tests with Topamax® (topiramate).
adverse drug reaction to other antiepileptics were
patch tested with the same preparation in pet.
Results
A positive patch test with the suspected drug (1+
or stronger) was observed in 18 of 56 patients
(32.1%), in 17 cases with antiepileptics and 1 with
tenoxicam.
In the group of 33 patients with antiepileptic-
induced DRESS, a positive result was observed
in 17 cases (51.5%). Carbamazepine alone was
responsible for 13 of 17 positive patch tests (Fig. 1),
followed by lamotrigine (2 cases), phenytoin (1
case) and Topamax® (1 case) (Fig. 2).
In overview, in the 18 patients where car-
bamazepine was suspected, 13 reacted positively
(72.2%), with 1+ or 2+ reactions (11 patients) and
with 3+ reactions (2 patients), apparently with no
correlation of the intensity of reaction and the clini-
cal score of the DRESS, although positive reactions
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Table 1. Patch tests results with antiepileptics and allopurinol
Culprit drugs Patients tested Positive patch tests % positive patch tests
Antiepileptics 33 17 51.5
Carbamazepine (1%, 5%, 10%, 20%a pet.) 18 13 72.2
Phenytoin (5%, 10% pet.) 7 1 14.3
Lamotrigine (1%, 10% pet.) 5 2 40
Phenobarbital (5%, 10% pet.) 2 0 0
Topamax® (topiramate, 30% in water and pet.) 1 1 100
Allopurinol (1%, 10%, 20% pet.)b 19 0 0
Oxypurinol (5%, 10% pet.)b 9 0 0
pet. – petrolatum.
aCarbamazepine was tested at 20% pet. in 20 patients.
bAllopurinol and oxypurinol were also tested at 10% in ethanol and water in three patients.
occurred in the more severe cases. Patients reacted
to all the concentrations of carbamazepine tested,
most of them with the more intense reaction at D2
or D3, and with no significant difference in reaction
intensity between the concentration of 1% and 20%.
Therefore, by increasing the concentration from 1%
to 20%, no more reactive patients were detected.
Relevance was confirmed by a positive accidental
rechallenge in one patient.
Although patients were tested with all the
antiepileptics, they reacted only to one drug, except
in one case: a patient with a carbamazepine-induced
DRESS that was reactivated with phenytoin reacted
simultaneously to carbamazepine and phenytoin on
patch testing.
None of the 19 patients patch tested with allop-
urinol nor the 9 tested with oxypurinol in several
concentrations and vehicles developed a positive
reaction (Table 1). In two of these patients addi-
tional lymphocyte activation tests performed with
allopurinol and oxypurinol were negative. Never-
theless, 2 of these 19 patients had a positive acci-
dental drug rechallenge: one had a maculopapular
exanthema with no systemic symptoms on the first
episode, and, 2 years later, a DRESS with allopuri-
nol readministration.
An isolated positive reaction was observed with
tenoxicam, but with no reaction to piroxicam,
meloxicam, or other NSAIDs.
There were no positive patch tests in controls and
no adverse reaction, namely no reactivation of skin
lesions or systemic symptoms during or after patch
testing.
There was no particular reactivity within the
European baseline series: 18 positive reactions
(32.1%) were observed, 6 patients had also pos-
itive patch tests to the suspected drugs, and 12
had isolated reactivity within the baseline series.
The main allergens within the baseline series were
nickel sulfate (55.5%), cobalt chloride (11.1%), and
p-phenylenediamine (11.1%).
Discussion
The usefulness of skin testing in the study of cuta-
neous adverse drug reactions, including patch, prick,
and intradermal testing with immediate and delayed
readings, varies significantly according to the drug
tested and the clinical features of the drug eruption,
and depends highly on patient selection (15, 24).
Considering only patch testing, reactivity occurs in
less than 50% of patients (19), varying from 10.8%
among 826 patients studied (25) to 43.9% in 66
patients (23).
It is not possible to perform patch testing during
the acute reaction; often there is no clear skin, and
iatrogenic immunosuppression might reduce skin
reactivity. Therefore, patch testing has to be delayed
at least 4–6 weeks after resolution of the cutaneous
adverse drug reaction.
As shown in our series, patch testing is generally
a safe procedure, including in severe adverse drug
reactions, like DRESS. Even when a drug is tested
at higher concentrations (20% pet.), the risk of
developing a severe reaction is unlikely to occur.
There is only one case published where patch
testing induced an exfoliative dermatitis; however,
it was performed using crushed tablets in pet. where
final drug concentration could not be adequately
controlled (26).
In several studies patch testing of patients with
DRESS have been included, but this pattern of
adverse drug reaction was not usually separated
from other maculopapular exanthemata or exfolia-
tive dermatitis, and, therefore, results on the value
of patch testing in DRESS have not been clearly
defined. Although drug-specific T-cells have been
isolated from the blood and skin in patients with
DRESS, the pathogenesis of this adverse drug reac-
tion seems to be much more complex with acute
viral reactivation and eventual viral – drug interac-
tions, and, therefore, patch tests performed after the
resolution of the adverse drug reaction might be
unable to reproduce drug skin hypersensitivity.
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In this study, 32.1% of patients with DRESS had
a positive patch test, which is in the normal range of
reactivity for other delayed cutaneous adverse drug
reactions (23, 25). Also, as in other drug reaction
patterns, the results of patch testing in DRESS are
highly dependent on the culprit drug (15, 24). This
is exemplified by divergent results in the two major
groups: reactivity of 51.5% in the antiepileptic group
and no reactivity at all in the allopurinol group.
In the antiepileptic group, patch test positivity
was high, particularly for carbamazepine (72.2%).
Previous studies have shown the usefulness of
patch testing in the diagnosis of hypersensitiv-
ity to antiepileptics, particularly for carbamazepine,
with positive reactions in 70–100% of the cases
studied (1, 12, 19, 27–30). Nevertheless, even for
carbamazepine, patch test reactivity depends on the
pattern of the cutaneous adverse drug reactions (30).
We have shown that in patients with DRESS reactiv-
ity to carbamazepine is high (72.2%), and, therefore,
patch testing is a very useful complementary test to
confirm its participation in this cutaneous adverse
drug reaction.
Although the recommended concentration for
testing most drugs in cutaneous adverse drug reac-
tions is 10% pet. (19), in the case of carbamazepine
we have previously tried to increase the concentra-
tion up to 20% to evaluate if we could detect more
reactive patients. We have previously shown, in dif-
ferent types of cutaneous adverse drug reactions
from carbamazepine, that patch testing yielded the
same results with concentrations of carbamazepine
ranging from 1% to 20% (31). In 1975, Houwerz-
ijl et al. reported six out of seven patients with
a severe rash and general symptoms with posi-
tive patch tests at all the concentrations of carba-
mazepine tested (10%, 20%, 40% pet.) (27), and
Silva et al. described three patients with exfoliative
erythroderma with strongly positive patch test reac-
tions to 1%, 2%, and 10% carbamazepine pet. (28).
Some authors have described positive reactions with
small drug concentrations, but no reactions to carba-
mazepine were elicited at concentrations lower than
0.1% (28–30). The present study, with all patients
reacting to carbamazepine at 1% and 20% pet., with
no significant difference in the intensity of the reac-
tion, suggests that a low concentration (1% pet.) is
also valuable for using in DRESS.
Positive patch tests in phenytoin-induced DRESS
are less frequent than for carbamazepine, and in
our study only one patient out seven had a positive
patch test to phenytoin at 5% and 10% pet., a result
similar to previous reports (32, 33). There are also
only some published reports with positive patch
tests to lamotrigine (32, 34). To our knowledge the
positive patch test reaction to topiramate is the
second described in the literature (35).
In cutaneous adverse drug reactions, cross-
reactivity among aromatic antiepileptics occurs
in about 80% of the individuals (1, 12), but this
cross-reactivity was not evidenced in patch test-
ing. Only one patient, with DRESS induced by
carbamazepine that worsened when phenytoin was
introduced on day 20, had a positive patch test to
both drugs. Some authors have suggested that the
supposed cross-reactions might not actually be due
to a chemical or antigenic similitude between them,
but rather to the fact that a second anticonvulsant
is administered during the immunologic depression
occurring during a first anticonvulsant-related
DRESS (36).
Allopurinol, a xanthine oxidase inhibitor widely
used to control plasma uric acid levels, is one of
the drugs frequently reported to cause DRESS (4).
When administered orally it is rapidly metabolized
to its oxidative metabolite 8-oxypurinol, which is
considered to be responsible for most of the actions
of allopurinol. In the 19 patients studied, patch tests
with allopurinol and its metabolite were always neg-
ative, as in our previous study involving 12 patients
with several types of cutaneous adverse drug reac-
tions to allopurinol, including 7 with DRESS (37)
Even though the molecular weight (136.11) of allop-
urinol is small we performed tape stripping before
applying the patches, but it did not enhance the
reactivity. The negativity of these patch tests can-
not exclude responsibility of allopurinol, as two of
these patients, who were accidentally rechallenged
orally, developed hypersensitivity. There are few
reports on patch testing with allopurinol, and we
found only one reference to a positive patch test
to a commercial formulation of allopurinol tested at
20% or 30% pet. among 10 patients studied (25), but
with no reference to the type of cutaneous adverse
drug reaction. There is no definite explanation for
the high number of false-negative results, but the-
oretically there may be several causes: (i) the final
responsible agent is another drug metabolite that is
not formed in the skin during patch testing; (ii) there
is no immune mechanism involved; (iii) concomi-
tant factors that are responsible in inducing transient
oral drug intolerance, such as viral infection, are
not present at the time of testing; and (iv) wrong
choice of vehicle, drug concentration, and exposure
time (23, 37).
Like patch testing, lymphocyte stimulation test-
ing in allopurinol-induced cutaneous adverse drug
reaction has also been inconclusive. In one single
report with three patients, Hamanaka et al. (38) had
significant lymphoproliferative reactions to oxypuri-
nol, not to allopurinol, which led them to consider
that DRESS was due to oxypurinol. However, our
studies do not seem to corroborate this possibility. In
order to better explore the non-reactors, intradermal
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testing could be tried in a hospital setting, although,
as allopurinol is not highly soluble in water, it might
be difficult to have a sterilized homogeneous prepa-
ration in saline for intradermal testing. Alternatively
we could try administration of the drug by ion-
tophoresis.
As a conclusion, we consider patch testing a safe
procedure to study patients with DRESS. Although
it is useful in patients with antiepileptic drug-
induced DRESS, where the proportion of relevant
and specific positive patch tests is high, when
allopurinol is the suspected drug, patch testing has
no value.
Apart from its usefulness in confirming the culprit
drug in DRESS, patch testing also contributes to
the understanding of the pathomechanisms involved.
A specific positive patch test reaction reinforces
the involvement of drug-dependent delayed hyper-
sensitivity mechanisms in this complex cutaneous
adverse drug reaction, and can be useful to collect
drug-specific T-cells for further studies.
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